Tango Therapeutics enters $100M ATM offering with Leerink, terminates Jefferies ATM program

Tango Therapeutics, Inc.

New $100M at-the-market common stock sales agreement with Leerink Partners as agent, dated Nov 21, 2025.
Agent commission of up to 3.0% of gross sales price per share sold under the agreement.
Prior $100M Jefferies ATM program terminated effective Nov 21, 2025, with no penalties.
Shares to be sold via at-the-market or negotiated transactions at company's discretion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.